Bajaj Healthcare Q2 FY27 Revenue Up 18.9% YoY to ₹175.9 Cr

Bajaj Healthcare Limited announced its unaudited financial results for Q2 and H1 FY27. For Q2 FY27, revenue from operations reached ₹175.9 Crore, an 18.9% increase year-over-year (YoY) and a 6.2% increase sequentially. EBITDA grew 12.2% YoY to ₹32.1 Crore, with the EBITDA margin improving to 18.2%. Profit after tax (PAT) surged 26.9% YoY to ₹14.1 Crore, resulting in an improved PAT margin of 8.0%. For H1 FY27, revenue increased 15.1% YoY to ₹341.5 Crore, and PAT grew 21.1% YoY to ₹27.8 Crore. Key business highlights include the successful launch of Cenobamate API and Tablets in India, with commercial launch commencing in September 2026. API exports grew 28.5% YoY, and formulations revenue saw an 82% YoY increase. The company also received an upgraded long-term rating from India Ratings & Research to IND A/Stable.